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Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few
data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this
issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years)
treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and
efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies;
according toSokal classification, 3 patients (4.6%)were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk,
whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas
11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were
reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued
DASbecause of toxicities. Pleural effusions (allWHOgrades) occurred in 12 patients (18.5%) and in 5 of themoccurred
during the first 3months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in
50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the
frontline treatment of CML patients N65 years old, proving efficacy and having a favorable safety profile also in elderly
subjects with comorbidities.
Neoplasia (2016) 18, 536–540Introduction
Imatinib (IM) frontline treatment in chronic myeloid leukemia
(CML) led to an excellent disease control in the vast majority of the
patients [1–3]. However, about one third of the patients discontinue
the drug due to treatment failure or toxicity [4,5] and require a salvage
therapy with second-generation tyrosine kinase inhibitors (2G-TKIs)
such as dasatinib (DAS) or nilotinib (NIL) [6–8].
Both these 2G-TKIs were very effective in patients resistant/intolerant
to IM, and their use was extended to the frontline treatment of newly
diagnosed CML patients. The DASISION and ENESTnd clinical trials
recently demonstrated a faster and deeper clinical efficacy of the 2G-TKIs
as compared with IM, leading to the approval of DAS and NIL as
alternative first-line option in CML patients [9,10].
However, both these company-sponsored studies recruited CML
patients according to well-defined protocol criteria, excluding many
patients for several reasons with a resulting median age of enrolled
subjects b50 years, compared with a median age of about 60 years in all
newly diagnosedCMLpatients in Italy [11]. Thus, these trials introduced
a selection bias, and the enrolled cohorts did not really reflect the whole
CML population observed in daily clinical practice [12].
This topic is particularly important in CML patients older than
65 years [13]. Older age and comorbidities were often considered as
exclusion criteria from clinical trials [14]. Recently, both the EUTOS
population-based registry and other studies provided more information
on the clinical characteristics, comorbidities, and epidemiology of patients
with CML in Europe and in the United States [15,16]. However, only
few and sparse data are reported in the current literature on 2G-TKIs in
patients older than 65 years with newly diagnosed CML, and this is still a
matter of debate.
To address this issue, we collected a “real-life” cohort of CML
patients in chronic phase older than 65 years and treated frontline with
DAS in 26 Italian centers from June 2012 to June 2015, focusing our
attention on toxicity and efficacy data.Patients and Methods
Patient Population
From June 2012 to June 2015, we identified a series of 65 patients
older than 65 years (M/F 32/33, median age 75.1 years, absolute
range 65.1-89.3, interquartile range [IR] 70.5-78.7) who were
diagnosed at 26 institutions as having early chronic phase CML with
the following characteristics:
- no prior TKIs treatment; but only hydroxyurea was permitted if
given for less than 3 months to reduce white blood cell count
- DAS as first-line treatment
Twelve of these patients (18.5%) were older than 80 years. The
main clinical features at diagnosis of the whole cohort are shown in
Table 1. As to comorbidities, only 6 patients (9.2%) did not have any
concomitant disease; on the contrary, 1 or 2 concomitant diseases
requiring specific treatments were present in 39 patients (60.1%), and
3 or more concomitant diseases were present in 20 patients (30.7%).
The five most common comorbidities are reported (Table 1).
Cytogenetic and Molecular Evaluation
Cytogenetic analyses were performed on bone marrow samples by
chromosome standard G or Q banding techniques in at least 20 cell
metaphases from direct or short-term (24-48 hours) cultures. If less than
20 metaphases were evaluable, fluorescence in situ hybridization on
interphase cells was performed with BCR-ABL extrasignal, dual-color,
dual-fusion probes.
Real-time quantitative polymerase chain reaction to assess BCR-ABL1
transcript levels was performed according to suggested procedures and
recommendations; results were expressed as BCR-ABL1/ABL1 ratio
according to the International Scale [17].
Cytogenetic and molecular responses were categorized according to
standard criteria: major cytogenetic response (MCyR) was defined by
Table 2. Main Clinical Features of Pleural Effusions
Patients with pleural effusion, n (%) 12 (18.5%)
Grade 1-2 9
Grade 3 3
Concomitant pericardial effusion, n 0
Median time from DAS start (months)
(IR)
3.4
(1.2-6.2)
Recurrence of pleural effusion, n (%) 7/12 (58.3%)
Table 1. Clinical Features at Diagnosis
No. of patients 65
Male, n (%) 32 (49.2)
Median age, years
(absolute range/IR)
75.1
(65.0-89.3/70.5-78.7)
Sokal risk: n (%)
Low 3 (4.6)
Intermediate 39 (60.0)
High 20 (30.8)
Not evaluable 3 (4.6)
Performance status (ECOG), n (%)
Grade 0-1 55 (84.6%)
Grade 2 10 (15.4%)
Median Hb, g/dl
(IR)
12.5
(11.4-13.8)
Median white blood cell count, ×109/l
(IR)
48.3
(27.8-93.7)
Median PLTs, ×109/l
(IR)
430
(243-803)
Spleen enlargement, cm below costal margin (%)
0 37 (57.0)
1-5 22 (33.8)
N 5 5 (7.7)
Not evaluable 1 (1.5)
Most common comorbidities, n (%):
Arterial hypertension 37 (56.9)
Diabetes 14 (21.5)
Dyslipidemia 13 (20.0)
Cardiovascular diseases 10 (15.3)
Previous/concomitant neoplasia 10 (15.3)
ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; PLTs, platelets.
Figure 1. Dose modifications at different time points.
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cytogenetic response (CCyR) by the presence of 100% Ph-negative
metaphases or as a number of positive marrow cell interphase nuclei less
than 2 of 200 (b1%) at fluorescence in situ hybridization analysis; major
molecular response (MMR) was defined as a BCR-ABL1/ABL1 ratio
b0.1% (MR 3.0), and deep molecular response as a BCR-ABL1/ABL1
ratio b0.01% (MR 4.0) or b0.0032% (MR 4.5) International Scale
(after internal standardization) [18]. Those patients who were evaluated
only with molecular analysis and had a BCR-ABL1/ABL1 ratio b1.0
were considered as in CCyR also [19].
Primary hematologic resistance to DAS was defined as failure to
achieve a complete hematologic remission after 3 months of treatment;
primary cytogenetic resistance to DAS was defined as failure to achieve
CCyR after 6 months of treatment. Secondary resistance to DAS was
defined as the loss of CCyR or the loss of MMR at any time after the
achievement of a previous CCyR or MMR.
Statistical Analysis
Calculations were expressed as mean ± SD for normally distributed
data, as median and IR for not-normally distributed data, or as
percentage frequencies; comparisons between groups of patients were
made by paired t test, χ2 test, and Fisher exact test, as appropriate, at
significance levels of P b .05. The Kaplan-Meier product-limit method
was used to estimate univariate survival curves, and the log-rank test was
adopted to compare the survival curves. Event-free survival (EFS) was
calculated from the date of DAS therapy start to any of the following
events: primary resistance to DAS, permanent DAS discontinuation
due to toxicity or any other unrelated cause, secondary resistance to
DAS, death due to any cause. Overall survival (OS) was calculated from
the date of DAS start to death due to any cause. All calculations were
made using a standard statistical package (SPSS for Windows Version
15.0, Chicago, IL).Results
Patient Therapy
Median interval fromCML diagnosis to DAS therapy was 23 days (IR
14-34). DAS starting dose was 100 mg once a day (OAD) in 54 patients
(83.0%), 80 mg OAD in 3 patients (4.7%), and 50 mg OAD in
8 patients (12.3%), respectively. The main reasons for a reduction in
the DAS starting dose were age over 80 years in 5 patients, severe
comorbidities in 4 patients, and physician judgment in 2 patients.
Treatment Toxicity
Hematologic toxicities of grade 3/4 were reported in 8 patients
(12.3%) after a median period of treatment of 1.1 months (IR
0.7-2.5), whereas grade 3/4 extrahematologic toxicities were reported
in 12 patients (18.5%) after a median treatment period of 4.6 months
(IR 0.8-13.7). There was no significant difference in hematologic
and extrahematologic toxicities, either of all WHO grades than of
grade 3/4, according to the initial dose of DAS.
Pleural effusions of all WHO grades occurred in 12 patients
(18.5%): in 5 of them, pleural effusions occurred during the first
3-month period of treatment. Permanent DAS discontinuation due
to pleural effusions was necessary in 6 patients (50.0% of those who
developed pleural effusions and 9.5% of the entire evaluated cohort).
The main clinical features of pleural effusions are shown in Table 2.
Overall, 10 patients (15.4%) permanently discontinued DAS due to
toxicity (2 patients in the first 3 months of treatment, 4 between the 4th
and 12th month, and 4 beyond that period). A different profile of dose
adaptation and permanent drug discontinuation was observed
according to the initial DAS dose. Twenty-six of 54 patients (48.1%)
required a dose reduction in the group treated with 100 mg as initial
dose as compared with 2 of 11 patients (18.1%) receiving less than
100 mg (P = .056). Moreover, all 10 patients who needed a permanent
treatment discontinuation because of toxicity have been treated with
100mg as initial dose. All dosemodifications at different time points are
shown in Figure 1.
Table 3. Cytogenetic and Molecular Response to DAS at Different Time Points
3rd Month 6th Month 12th Month
Too early / 1 7
Evaluable 65 64 58
Not done 6 (9.3%) 6 (9.4%) /
Discontinuation 2 (3.1%) 4 (6.2%) 7 (12.1%)
Less than CCyR 10 (15.3%) 5 (7.8%) 3 (5.1%)
CCyR * 47 (72.3%) 49 (76.6%) 48 (82.8%)
MMR 19 (29.2%) 36 (56.2%) 37 (63.8%)
MR 3.0 13 16 20
MR 4.0 4 13 9
MR 4.5 2 7 8
* Patients at any time point with molecular analysis only and BCR-ABL1/ABL1 ratio b1.0 were also
considered in CCyR.
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All patients attained a complete hematologic response. After a
median period of treatment of 17.0 months (IR 11.9-24.2), all of them
were evaluable for cumulative response, with at least one cytogenetic
and/or molecular evaluation performed. Two patients (3.1%) needed
an early treatment discontinuation due to toxicity and were considered
as failure; another 2 (3.1%) had a primary cytogenetic resistance, and
1 (1.5%) achieved a PCyR only. The remaining 60 patients (92.3%)
achieved a CCyR and 50 of them (76.9%) also an MMR. Response to
treatment at different time points is shown in Table 3. At the 3-month
time point, early molecular response (BCR-ABL1/ABL1 ratio b10%)
was achieved by 49 of 52 evaluable patients (94.2%); at the 6-month
time point, early molecular response (BCR-ABL1/ABL1 ratio b1.0%)
was achieved by 46 of 49 evaluable patients (93.8%).
Follow-Up
At the last follow-up, after a median period of observation of
19.3 months (IR 14.3-25.6), 59 patients are still alive and 48 of them
are still receiving DAS treatment. Only 1 patient (1.5%) developed a
blast phase after 13.5 months of therapy and is still alive and in
treatment with ponatinib. Four patients died while in MMR (three
cases) or in CHR (one case) from CML-unrelated causes (heart failure
in two cases; acute myocardial infarction and senectus in one case,
respectively), and two patients were lost to follow-up.Figure 2. CumulativeThe 12-month and 24-month cumulative EFSs were 85.4% (95%
confidence interval [CI] 76.6-94.2) and 69.3% (95% CI 55.2-83.4),
respectively (Figure 2A): the 12-month and 24-month cumulative OSs
were 98.3% (95% CI 95.0-100) and 89.9% (95% CI 80.1-99.7),
respectively (Figure 2B).
Discussion
Efficacy and safety of IM in patients older than 65 years with CML
were already demonstrated in many clinical studies and real-life
analyses; however, as in younger subjects, the response to IM remains
unsatisfactory in about one third of patients.
The introduction of more potent but also more toxic 2G-TKIs in
the frontline therapy of CML leads to the question of whether or not
patients older than 65 years could be safely treated with these drugs.
In the setting of controlled clinical trials, we can only have data on
tolerability and efficacy in very fit and compliant patients older than
65 years but not on the whole real-life elderly population. The selection
bias present in these trials becomes evident when we look at the
exclusion criteria and at the median age of the enrolled cohorts, which is
lower than the median age of CML unselected patients in the most
important epidemiological registries [20]. In both the DASISION and
ENESTnd trials, median age was lower than 50 years and the rate of
patients aged over 65 years was lower than 15% (36/246 [12.7%] and
27/281 [9.6%] in the NIL 300-mg and in the NIL 400-mg arms of
ENESTnd, respectively, and 20/259 [7.7%] in the DAS arm of
DASISION).
Therefore, to test feasibility of 2G-TKIs in patients older than 65 years,
postapproval data from the current clinical practice are needed. At present,
however, there is no report available in the literature on this issue.
We are aware that a selection was also made in our cohort, as many
physicians still consider IM therapy the best frontline drug for
patients older than 65 years. It is reasonable that, in our centers,
low-risk or very frail patients older than 65 years probably did not
receive DAS as frontline therapy and were not included in our
real-life cohort.
However, the median age of our cohort was remarkably high, with
about 50% of patients older than 75 years. Furthermore, a major point
was the incidence in our cohort of concomitant diseases: it is worthEFS (A) and OS (B).
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active treatments and that an Eastern Cooperative Oncology Group
performance status = 2 was reported in 16% of patients.
In this context, DAS treatment was safe, grade 3 to 4 hematological
and extrahematological toxicities were acceptable, and the incidence
of pleural effusions was comparable to that observed in clinical
controlled trials in the same age group. The rate of permanent
treatment discontinuation at 12 months was less than 15%, and it
was similar to the rate observed in the DASISION trial [21].
Treatment results were also encouraging, with a high rate of
cumulative CCyR (N90%) and MMR (N70%). These results were
not affected by the initial DAS dosage: moreover, none of the patients
who received lower DAS initial dose needed to stop the treatment for
toxicities. Recent data from the OPTIM-Dasatinib study suggested
that also a dose of DAS b100 mg could be effective with a lower
toxicity [22]; the small sample size of our cohort did not allow us to
spread any conclusion on the clinical value of a reduced DAS dose in
this group of patients. In the future, however, an individualized
approach, consisting of a reduced starting dose with progressive
modifications based on response and toxicity, could be useful at least
in some patient older than 65 years with comorbidities.
In conclusion, present data show that DAS could play a major role in
the frontline treatment also in real-life patients aged over 65 years and
with comorbidities, being effective and having a favorable safety profile.
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